Meridian Bioscience Stock Price, News & Analysis (NASDAQ:VIVO)

$14.50 -0.05 (-0.34 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$14.50
Today's Range$14.35 - $14.85
52-Week Range$12.45 - $16.45
Volume204,139 shs
Average Volume293,227 shs
Market Capitalization$613.46 million
P/E Ratio25.44
Dividend Yield3.45%
Beta0.98

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorHealthcare
SymbolNASDAQ:VIVO
CUSIP58958410
Phone+1-513-2713700

Debt

Debt-to-Equity Ratio0.28%
Current Ratio5.82%
Quick Ratio3.96%

Price-To-Earnings

Trailing P/E Ratio25.4385964912281
Forward P/E Ratio20.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$200.77 million
Price / Sales3.06
Cash Flow$1.05 per share
Price / Cash13.79
Book Value$4.09 per share
Price / Book3.55

Profitability

Trailing EPS$0.57
Net Income$21.55 million
Net Margins10.46%
Return on Equity17.00%
Return on Assets11.59%

Miscellaneous

Employees640
Outstanding Shares42,310,000

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience announced a quarterly dividend on Wednesday, January 24th. Investors of record on Monday, February 5th will be given a dividend of $0.125 per share on Thursday, February 15th. This represents a $0.50 annualized dividend and a yield of 3.45%. The ex-dividend date is Friday, February 2nd. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings results on Thursday, January, 25th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.14 by $0.01. The business earned $52.30 million during the quarter, compared to analyst estimates of $49 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.00%. Meridian Bioscience's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. View Meridian Bioscience's Earnings History.

When will Meridian Bioscience make its next earnings announcement?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share (EPS) guidance of $0.65-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $207-212 million, compared to the consensus revenue estimate of $207.18 million.

Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2018?

2 Wall Street analysts have issued 1-year target prices for Meridian Bioscience's stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Meridian Bioscience's share price to reach $16.00 in the next twelve months. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:

  • John A. Kraeutler, Executive Chairman of the Board (Age 69)
  • Richard L. Eberly, Executive Vice President, President, Chief Commercial Officer (Age 56)
  • John P. Kenny, Chief Executive Officer, Director (Age 49)
  • Melissa A. Lueke, Chief Financial Officer, Executive Vice President, Secretary (Age 54)
  • Marco G. Calzavara, President and Managing Director of Meridian Bioscience Europe (Age 63)
  • Lawrence J. Baldini, Executive Vice President and President - Global Operations (Age 58)
  • Vecheslav A. Elagin Ph.D., Executive Vice President - Research and Development (Age 50)
  • Susan D. Rolih, Executive Vice President - Regulatory & Quality Systems (Age 68)
  • Amy M. Winslow, Executive Vice President, President and Chief Executive Officer - Magellan (Age 46)
  • David C. Phillips, Lead Independent Director (Age 79)

Who owns Meridian Bioscience stock?

Meridian Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.46%), Brown Capital Management LLC (11.03%), Renaissance Technologies LLC (5.27%), Millennium Management LLC (2.68%), Systematic Financial Management LP (2.10%) and Bank of New York Mellon Corp (1.88%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?

Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, Citadel Advisors LLC, Goldman Sachs Group Inc., Gotham Asset Management LLC, Metropolitan Life Insurance Co. NY and Guggenheim Capital LLC. View Insider Buying and Selling for Meridian Bioscience.

Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?

Meridian Bioscience's stock was purchased by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, Millennium Management LLC, Assenagon Asset Management S.A., Deutsche Bank AG, Renaissance Technologies LLC, American Century Companies Inc., Geode Capital Management LLC and BlackRock Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy Meridian Bioscience stock?

Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of Meridian Bioscience stock can currently be purchased for approximately $14.50.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $613.46 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.57 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 River Hills Dr, CINCINNATI, OH 45244, United States. The company can be reached via phone at +1-513-2713700.


MarketBeat Community Rating for Meridian Bioscience (VIVO)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Meridian Bioscience (NASDAQ:VIVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.001.751.751.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$11.50$11.50$14.33
Price Target Upside: 0.00% downside23.08% downside23.08% downside5.39% downside

Meridian Bioscience (NASDAQ:VIVO) Consensus Price Target History

Price Target History for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018Canaccord GenuityBoost Price TargetHold -> Hold$14.00 -> $16.00LowView Rating Details
3/28/2017CL KingInitiated CoverageNeutral -> NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Meridian Bioscience (NASDAQ:VIVO) Earnings History and Estimates Chart

Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
1/25/2018Q1 2018$0.14$0.15$49.00 million$52.30 millionViewN/AView Earnings Details
11/9/2017Q4 2017$0.15$0.15$48.28 million$49.70 millionViewN/AView Earnings Details
7/27/2017Q3 2017$0.16$0.16$49.13 million$50.14 millionViewN/AView Earnings Details
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
11/11/2010Q4 2010$0.18$0.15ViewN/AView Earnings Details
7/20/2010Q3 2010$0.18$0.17ViewN/AView Earnings Details
4/20/2010Q2 2010$0.14$0.15ViewN/AView Earnings Details
1/21/2010Q1 2010$0.23$0.22ViewN/AView Earnings Details
11/12/2009Q4 2009$0.21$0.22ViewN/AView Earnings Details
7/16/2009Q3 2009$0.20$0.21ViewN/AView Earnings Details
4/16/2009Q2 2009$0.22$0.18ViewN/AView Earnings Details
1/22/2009Q1 2009$0.20$0.20ViewN/AView Earnings Details
11/12/2008Q4 2008$0.18$0.19ViewN/AView Earnings Details
7/17/2008Q3 2008$0.19$0.19ViewN/AView Earnings Details
4/17/2008Q2 2008$0.19$0.18ViewN/AView Earnings Details
1/22/2008Q1 2008$0.17$0.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Meridian Bioscience (NASDAQ:VIVO) Earnings Estimates

2018 EPS Consensus Estimate: $0.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.17$0.17$0.17
Q2 20181$0.22$0.22$0.22
Q3 20181$0.17$0.17$0.17
Q4 20181$0.16$0.16$0.16
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Meridian Bioscience (NASDAQ:VIVO) Dividend Information

Most Recent Dividend:2/15/2018
Annual Dividend:$0.50
Dividend Yield:3.45%
Payout Ratio:87.72% (Trailing 12 Months of Earnings)
70.42% (Based on This Year's Estimates)
64.94% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ:VIVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/24/2018Quarterly$0.130.00771604938271605%2/2/20182/5/20182/15/2018
11/8/2017Quarterly$0.133.44%11/17/201711/20/201711/30/2017
7/27/2017Quarterly$0.133.55%8/3/20178/7/20178/17/2017
4/27/2017quarterly$0.133.33%5/4/20175/8/20175/18/2017
1/25/2017quarterly$0.133.91%2/2/20172/6/20172/16/2017
11/10/2016Quarterly$0.204.6%11/17/201611/21/201612/1/2016
7/28/2016quarterly$0.204.13%8/4/20168/8/20168/18/2016
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013
12/4/2012quarterly$0.1912/14/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Meridian Bioscience (NASDAQ VIVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 85.37%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience (NASDAQ VIVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2018John Mccune Jr. RiceDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/24/2017John A KraeutlerChairmanBuy7,000$13.67$95,690.00345,230View SEC Filing  
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00167,071View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00106,934View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.9052,926View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.407,000View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.0048,719View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00316,683View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.0095,501View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.003,000View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.007,700View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.0054,459View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.7446,219View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.3450,500View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48106,702View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.0040,755View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.7675,500View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50270,718View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Meridian Bioscience (NASDAQ VIVO) News Headlines

Source:
DateHeadline
Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 MillionMeridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 Million
www.americanbankingnews.com - February 14 at 12:46 PM
Lawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders FoundationLawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders Foundation
finance.yahoo.com - February 12 at 3:33 PM
 Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS
www.americanbankingnews.com - February 12 at 5:12 AM
Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 SharesMeridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares
www.americanbankingnews.com - February 8 at 4:20 AM
Active-Investors: Free Post Earnings Research Report: Meridians Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%Active-Investors: Free Post Earnings Research Report: Meridian's Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%
www.finanznachrichten.de - February 5 at 8:00 AM
Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%
finance.yahoo.com - February 5 at 8:00 AM
Meridian Bioscience (VIVO) Downgraded to Sell at BidaskClubMeridian Bioscience (VIVO) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - February 3 at 1:38 PM
William Blair Comments on Meridian Bioscience, Inc.s FY2019 Earnings (VIVO)William Blair Comments on Meridian Bioscience, Inc.'s FY2019 Earnings (VIVO)
www.americanbankingnews.com - January 29 at 7:46 AM
Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13
www.americanbankingnews.com - January 28 at 7:31 AM
 Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million
www.americanbankingnews.com - January 28 at 5:48 AM
Meridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord GenuityMeridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord Genuity
www.americanbankingnews.com - January 26 at 3:18 PM
Head-To-Head Analysis: Zimmer Biomet (ZBH) & Meridian Bioscience (VIVO)Head-To-Head Analysis: Zimmer Biomet (ZBH) & Meridian Bioscience (VIVO)
www.americanbankingnews.com - January 26 at 1:30 PM
Meridian Bioscience, Inc. (VIVO) Expected to Announce Earnings of $0.14 Per ShareMeridian Bioscience, Inc. (VIVO) Expected to Announce Earnings of $0.14 Per Share
www.americanbankingnews.com - January 26 at 5:22 AM
Meridian Bioscience (VIVO) Issues Quarterly  Earnings Results, Beats Estimates By $0.01 EPSMeridian Bioscience (VIVO) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - January 25 at 9:26 AM
Meridian Bioscience (VIVO) Releases FY18 Earnings GuidanceMeridian Bioscience (VIVO) Releases FY18 Earnings Guidance
www.americanbankingnews.com - January 25 at 9:14 AM
Meridian Bioscience beats 1Q profit forecastsMeridian Bioscience beats 1Q profit forecasts
finance.yahoo.com - January 25 at 7:55 AM
Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 GuidanceMeridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
finance.yahoo.com - January 25 at 7:55 AM
Meridian Bioscience (VIVO) Set to Announce Quarterly Earnings on ThursdayMeridian Bioscience (VIVO) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - January 24 at 10:58 PM
Meridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment ResearchMeridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 21 at 8:42 AM
Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018
finance.yahoo.com - January 19 at 4:44 PM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 16 at 4:22 PM
The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO)The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO)
finance.yahoo.com - January 15 at 4:23 PM
UPCOMING DEADLINE: The Klein Law Firm Reminds Investors of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO)UPCOMING DEADLINE: The Klein Law Firm Reminds Investors of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018 (VIVO)
finance.yahoo.com - January 13 at 10:25 AM
MERIDIAN BIOSCIENCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc. - VIVOMERIDIAN BIOSCIENCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc. - VIVO
finance.yahoo.com - January 13 at 10:25 AM
Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)
finance.yahoo.com - January 13 at 10:25 AM
VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors ...VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors ...
www.businesswire.com - January 11 at 4:28 PM
Greater Cincinnati firm faces lawsuits linked to FDA warning, stock dipGreater Cincinnati firm faces lawsuits linked to FDA warning, stock dip
finance.yahoo.com - January 11 at 4:28 PM
Zacks: Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $49.74 MillionZacks: Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $49.74 Million
www.americanbankingnews.com - January 11 at 1:58 PM
VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the FirmVIVO INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - January 10 at 4:23 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 10 at 10:39 AM
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm (VIVO)Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Meridian Bioscience, Inc. Investors and Encourages Investors to Contact the Firm (VIVO)
www.businesswire.com - January 8 at 4:29 PM
VIVO LOSS NOTICE: Rosen Law Firm Reminds Meridian Bioscience, Inc. Investors of Important Deadline in Class Action – VIVOVIVO LOSS NOTICE: Rosen Law Firm Reminds Meridian Bioscience, Inc. Investors of Important Deadline in Class Action – VIVO
finance.yahoo.com - January 8 at 10:44 AM
Meridian Bioscience, Inc. (VIVO) Receives Consensus Recommendation of "Hold" from BrokeragesMeridian Bioscience, Inc. (VIVO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 8 at 4:36 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVOSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVO
finance.yahoo.com - January 7 at 12:39 PM
Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVOPomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO
www.finanznachrichten.de - January 6 at 10:31 AM
MERIDIAN BIOSCIENCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc ...MERIDIAN BIOSCIENCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Meridian Bioscience, Inc ...
www.businesswire.com - January 6 at 10:31 AM
VIVO INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Meridian Bioscience, Inc. InvestorsVIVO INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Meridian Bioscience, Inc. Investors
finance.yahoo.com - January 4 at 10:31 AM
VIVO EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018VIVO EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Meridian Bioscience, Inc. and a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - January 4 at 10:31 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Meridian Bioscience, Inc. (VIVO) & Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - January 3 at 4:24 PM
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVOEQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVO
finance.yahoo.com - January 3 at 4:24 PM
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact The FirmFINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact The Firm
finance.yahoo.com - January 3 at 4:24 PM
FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact The FirmFINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Meridian Bioscience, Inc. (NASDAQ: VIVO) To Contact The Firm
feeds.benzinga.com - January 3 at 3:22 PM
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Meridian Bioscience, Inc.Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Meridian Bioscience, Inc.
finance.yahoo.com - January 2 at 10:25 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVOINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018 -- VIVO
finance.yahoo.com - December 28 at 3:19 PM
The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018The Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - December 27 at 1:16 PM
Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $49.74 MillionMeridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $49.74 Million
www.americanbankingnews.com - December 25 at 6:56 AM
Financial Survey: Meridian Bioscience (VIVO) vs. Halyard Health (HYH)Financial Survey: Meridian Bioscience (VIVO) vs. Halyard Health (HYH)
www.americanbankingnews.com - December 24 at 5:15 AM
$0.14 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter$0.14 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter
www.americanbankingnews.com - December 23 at 5:22 PM
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Meridian Bioscience, Inc. to Contact the FirmDEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Meridian Bioscience, Inc. to Contact the Firm
finance.yahoo.com - December 18 at 4:20 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Meridian Bioscience, Inc. and Set a Lead Plaintiff Deadline of January 16, 2018
finance.yahoo.com - December 18 at 4:20 PM

SEC Filings

Meridian Bioscience (NASDAQ:VIVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Meridian Bioscience (NASDAQ:VIVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Meridian Bioscience (NASDAQ VIVO) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.